Evidence map›Paper›PMID 41485003›Full record

ArticleInfectious diseases of poverty2026

Clinical spectrum, immune status, and prognostic factors of cryptococcosis: insights from a large, multi-center, ambispective cohort study in southeastern China.

Lei Gu, Jing Lin, Anmao Li, Jian Yue, Wen Wen, Wei Liu, Qunying Lin, Xiangqi Chen, Xiaohong Chen, Jun Wu and 4 more

Abstract readMulticenter Study
In one paragraph

Article in Infectious diseases of poverty, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lei Gu *Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Jing Lin *Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Anmao Li *Department of Rheumatology and Immunology, Affliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Jian Yue *The People's Hospital of Gaozhou, Gaozhou, 525200, China.
Wen Wen *Department of Pulmonary and Critical Care Medicine, Fuzong Clinical Medical College of Fujian Medical University, Dongfang Hospital of Xiamen University, School of Medicine, Xiamen University, 900th Hospital of PLA Joint Logistic Support Force, Fuzhou, 350001, China.
Wei Liu *Department of Pulmonary and Critical Care Medicine, Fuzong Clinical Medical College of Fujian Medical University, Dongfang Hospital of Xiamen University, School of Medicine, Xiamen University, 900th Hospital of PLA Joint Logistic Support Force, Fuzhou, 350001, China.
Qunying LinDepartment of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Putian University, Putian, 351100, China.
Xiangqi ChenDepartment of Pulmonary and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, 350001, China.
Xiaohong ChenDepartment of Pulmonary and Critical Care Medicine, Fuzhou Pulmonary Hospital of Fujian, Fujian Medical University Clinical Teaching Hospital, Fuzhou, 350001, China.
Jun WuDepartment of Pulmonary and Critical Care Medicine, The Second Hospital of Nanping, Nanping, 353000, China.
Zeyi LiuDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. liuzeyisuda@163.com.
Baosong XieDepartment of Pulmonary and Critical Care Medicine, Fuzhou University Affiliated Provincial Hospital, Fuzhou, 350001, China. xbaosong@126.com.
Guoxiang LaiDepartment of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, 350003, China. laiguoxiang2007@163.com.
Jian-An HuangDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. huang_jian_an@163.com.

Funding

BoXi cultivation program of the First Affiliated Hospital of Soochow University BXQN2024009China Postdoctoral Science Foundation 2024M762314Jiangsu Funding Program for Excellent Postdoctoral Talent 2024ZB410Natural Science Foundation of Jiangsu Province BK20240365the open project of Chongqing Key Laboratory of Emergency Medicine 2024KFKTZD02
6 · The paper itself

Abstract

backgroundCryptococcosis is a major opportunistic fungal infection with heterogeneous clinical outcomes; however, data on clinical features and prognostic factors in non-HIV populations remain limited. This study aimed to provide real-world evidence on the clinical characteristics, immune stratification, diagnostic performance, treatment patterns, and outcomes of cryptococcosis.

methodsWe performed a multi-center ambispective cohort study of patients with cryptococcosis diagnosed between 2013 and 2025 across 48 hospitals in southeastern China, including Jiangsu and Fujian provinces. Patients were stratified according to immune status, disease type, and prognosis. Categorical variables were compared using the chi-square test or Fisher's exact test, and continuous variables were analyzed using the Mann-Whitney U test or Kruskal-Wallis test, as appropriate.

resultsA total of 396 patients were included, with a median age of 52 years; 61.9% were male. Most patients were immunocompetent (57.1%), while 33.1% had mild and 9.9% severe immunodeficiency. Pulmonary disease predominated (89.7%), whereas 10.1% had meningitis/dissemination. Severe immunodeficiency (SID) was associated with fever, neurological symptoms, lymphopenia, and elevated C-reactive protein (CRP) (all P < 0.01). Patients with meningitis/dissemination had more neurological manifestations and a markedly worse prognosis than those with pulmonary disease (mortality 35.1% vs. 2.1%). Among 319 patients with available follow-up data, follow-up duration varied from several days to several years, with prospective patients followed for up to 12 months. Overall, 89.0% recovered or improved, while 6.0% deteriorated or died. Poor outcomes were associated with older age, SID, central nervous system (CNS) involvement, lymphopenia, and elevated CRP. Serum cryptococcal antigen (CrAg) assays showed 94.6% concordance (122/129) between qualitative and quantitative methods. Quantitative ELISA identified four additional positive cases but missed three qualitative positive cases. In pulmonary cryptococcosis, amphotericin B-containing regimens were rarely used, while azole monotherapy was administered to over 95% of patients across severity groups and achieved favorable outcomes.

conclusionsHost immune status, CNS involvement, and systemic inflammation are key predictors of outcome in cryptococcosis. Quantitative and qualitative CrAg assays demonstrate high diagnostic performance and azole monotherapy remained effective for pulmonary disease. These findings support risk-stratified diagnostic and therapeutic strategies in routine clinical practice, particularly in resource-limited settings.

Indexed as

CryptococcosisAdultAgedAntifungal AgentsChinaCohort StudiesFemaleHumansMaleMiddle AgedPrognosisYoung AdultAntifungal AgentsAntifungal therapyCryptococcal antigenCryptococcal meningitisCryptococcosisImmune statusPrognosis

Identifiers

PMID41485003
PMCPMC12765305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.